Vivimed Labs — 360° view

Vivimed Labs, a company in the Pharmaceuticals industry, reported revenue of ₹12 crore and a net loss of ₹147 crore for the March 2026 quarter.

Vivimed Labs (NSE: VIVIMEDLAB-BZ) closed at ₹5.02 on 20 Nov 2026. Its market capitalisation is ₹42 crore.

Share price
₹5.02 (20 Nov 2026)
Market cap
₹42 Cr (20 Nov 2026)
Revenue
₹12 Cr (March 2026 quarter)
Net profit
₹-147 Cr (March 2026 quarter)
ROCE
-65.2% (FY26)
ROE
% (FY26)
Book value
₹-25.4 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: VIVIMEDLAB-BZ

Vivimed Labs Ltd, established in 1988, is primarily engaged in the Business of Active Pharmaceuticals Ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals and Retail Branded Formulation manufacturing.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.